Narrowband UVB Treatment in Patients With Vitiligo

Completed · Not applicable

Conditions studied: Vitiligo

In brief

The study offers narrowband UVB light therapy to patients who have 5% of their body involved with vitiligo. The hypothesis is that Narrowband UVB promotes melanocyte proliferation in vitiligo lesions.

Key facts

Study ID

NCT00398723

Run by

Mary Sullivan-Whalen

People needed

20

Starts

2006-11-01

Expected to finish

2007-11-01

Last updated by the study team

2011-10-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years of age or greater
• Vitiligo with extensive skin involvement (>5% body surface affected).

You may not qualify if…

• No treatment with topical steroids, calcineurin inhibitors or vitamin D analogs for at least 4 weeks prior to entering the study.
• No treatment with systemic therapies, including methotrexate, etretinate, PUVA, or cyclosporine 4 weeks prior to entering the study.

Where it is running

• Rockefeller University Hospital — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.